Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model - Takeaways - MDSpire

Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model

  • By

  • Liang Zhang

  • Jacqueline Wax

  • Torsten Goldmann

  • Afsaneh Mehrpouyan

  • Antje Müller

  • Frank Petersen

  • Gabriela Riemekasten

  • Xinhua Yu

  • June 5, 2026

  • 0 min

Share

  • 1

    Tocilizumab effectively reduced systemic inflammation and disease severity in a humanized mouse model of systemic sclerosis (SSc).

  • 2

    Siltuximab, targeting human IL-6, failed to prevent disease development in the same model due to immune complex accumulation.

  • 3

    The study utilized a PBMC transfer-induced humanized mouse model to investigate the role of IL-6 in systemic inflammation.

  • 4

    Elevated human IL-6 levels were observed in both SSc patients and their corresponding mouse models.

  • 5

    The findings underscore the therapeutic potential of IL-6 receptor blockade in managing systemic inflammation.

Original Source(s)

Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model

  • by Liang Zhang, Jacqueline Wax, Torsten Goldmann, Afsaneh Mehrpouyan, Antje Müller, Frank Petersen, Gabriela Riemekasten, Xinhua Yu

  • June 5, 2026

Related Content

Correction: Trends in cardiovascular mortality related to rheumatoid arthritis among U.S. adults, 1999–2023

NF-κB signaling in osteoarthritis: integrating mechanical stress, innate immunity, and cartilage degeneration

Normal serum uric acid gout: a neglected and challenging condition